Literature DB >> 33741942

A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes.

Camila H Coelho1, Wai Kwan Tang2, Martin Burkhardt3, Jacob D Galson4,5, Olga Muratova3, Nichole D Salinas2, Thiago Luiz Alves E Silva6, Karine Reiter3, Nicholas J MacDonald3, Vu Nguyen3, Raul Herrera3, Richard Shimp3, David L Narum3, Miranda Byrne-Steele7, Wenjing Pan7, Xiaohong Hou7, Brittany Brown7, Mary Eisenhower7, Jian Han7, Bethany J Jenkins1, Justin Y A Doritchamou1, Margery G Smelkinson8, Joel Vega-Rodríguez6, Johannes Trück4, Justin J Taylor9, Issaka Sagara10, Sara A Healy3, Jonathan P Renn3, Niraj H Tolia11, Patrick E Duffy12,13.   

Abstract

Malaria elimination requires tools that interrupt parasite transmission. Here, we characterize B cell receptor responses among Malian adults vaccinated against the first domain of the cysteine-rich 230 kDa gamete surface protein Pfs230, a key protein in sexual stage development of P. falciparum parasites. Among nine Pfs230 human monoclonal antibodies (mAbs) that we generated, one potently blocks transmission to mosquitoes in a complement-dependent manner and reacts to the gamete surface; the other eight show only low or no blocking activity. The structure of the transmission-blocking mAb in complex with vaccine antigen reveals a large discontinuous conformational epitope, specific to domain 1 of Pfs230 and comprising six structural elements in the protein. The epitope is conserved, suggesting the transmission-blocking mAb is broadly functional. This study provides a rational basis to improve malaria vaccines and develop therapeutic antibodies for malaria elimination.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33741942      PMCID: PMC7979743          DOI: 10.1038/s41467-021-21955-1

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   17.694


  43 in total

1.  Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production.

Authors:  Saliha Eksi; Beata Czesny; Geert-Jan van Gemert; Robert W Sauerwein; Wijnand Eling; Kim C Williamson
Journal:  Mol Microbiol       Date:  2006-08       Impact factor: 3.501

2.  Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes.

Authors:  K C Williamson; D B Keister; O Muratova; D C Kaslow
Journal:  Mol Biochem Parasitol       Date:  1995-12       Impact factor: 1.759

Review 3.  Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction.

Authors:  Camila H Coelho; Rino Rappuoli; Peter J Hotez; Patrick E Duffy
Journal:  Trends Parasitol       Date:  2019-05-29

4.  Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.

Authors:  Gianna Triller; Stephen W Scally; Giulia Costa; Maria Pissarev; Cornelia Kreschel; Alexandre Bosch; Eric Marois; Brandon K Sack; Rajagopal Murugan; Ahmed M Salman; Chris J Janse; Shahid M Khan; Stefan H I Kappe; Ayola A Adegnika; Benjamin Mordmüller; Elena A Levashina; Jean-Philippe Julien; Hedda Wardemann
Journal:  Immunity       Date:  2017-11-29       Impact factor: 31.745

5.  Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins.

Authors:  Kavita Singh; Martin Burkhardt; Sofia Nakuchima; Raul Herrera; Olga Muratova; Apostolos G Gittis; Emily Kelnhofer; Karine Reiter; Margery Smelkinson; Daniel Veltri; Bruce J Swihart; Richard Shimp; Vu Nguyen; Baoshan Zhang; Nicholas J MacDonald; Patrick E Duffy; David N Garboczi; David L Narum
Journal:  Commun Biol       Date:  2020-07-24

6.  Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies.

Authors:  Daniel G W Alanine; Doris Quinkert; Rasika Kumarasingha; Shahid Mehmood; Francesca R Donnellan; Nana K Minkah; Bernadeta Dadonaite; Ababacar Diouf; Francis Galaway; Sarah E Silk; Abhishek Jamwal; Jennifer M Marshall; Kazutoyo Miura; Lander Foquet; Sean C Elias; Geneviève M Labbé; Alexander D Douglas; Jing Jin; Ruth O Payne; Joseph J Illingworth; David J Pattinson; David Pulido; Barnabas G Williams; Willem A de Jongh; Gavin J Wright; Stefan H I Kappe; Carol V Robinson; Carole A Long; Brendan S Crabb; Paul R Gilson; Matthew K Higgins; Simon J Draper
Journal:  Cell       Date:  2019-06-13       Impact factor: 41.582

7.  Identification of domains within Pfs230 that elicit transmission blocking antibody responses.

Authors:  Mayumi Tachibana; Kazutoyo Miura; Eizo Takashima; Masayuki Morita; Hikaru Nagaoka; Luwen Zhou; Carole A Long; C Richter King; Motomi Torii; Takafumi Tsuboi; Tomoko Ishino
Journal:  Vaccine       Date:  2019-02-26       Impact factor: 3.641

Review 8.  Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design.

Authors:  Rino Rappuoli; Matthew J Bottomley; Ugo D'Oro; Oretta Finco; Ennio De Gregorio
Journal:  J Exp Med       Date:  2016-03-28       Impact factor: 14.307

9.  A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens.

Authors:  Joshua Tan; Kathrin Pieper; Luca Piccoli; Peter Bull; Antonio Lanzavecchia; Abdirahman Abdi; Mathilde Foglierini Perez; Roger Geiger; Claire Maria Tully; David Jarrossay; Francis Maina Ndungu; Juliana Wambua; Philip Bejon; Chiara Silacci Fregni; Blanca Fernandez-Rodriguez; Sonia Barbieri; Siro Bianchi; Kevin Marsh; Vandana Thathy; Davide Corti; Federica Sallusto
Journal:  Nature       Date:  2015-12-23       Impact factor: 49.962

10.  A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Authors:  Neville K Kisalu; Azza H Idris; Connor Weidle; Yevel Flores-Garcia; Barbara J Flynn; Brandon K Sack; Sean Murphy; Arne Schön; Ernesto Freire; Joseph R Francica; Alex B Miller; Jason Gregory; Sandra March; Hua-Xin Liao; Barton F Haynes; Kevin Wiehe; Ashley M Trama; Kevin O Saunders; Morgan A Gladden; Anthony Monroe; Mattia Bonsignori; Masaru Kanekiyo; Adam K Wheatley; Adrian B McDermott; S Katie Farney; Gwo-Yu Chuang; Baoshan Zhang; Natasha Kc; Sumana Chakravarty; Peter D Kwong; Photini Sinnis; Sangeeta N Bhatia; Stefan H I Kappe; B Kim Lee Sim; Stephen L Hoffman; Fidel Zavala; Marie Pancera; Robert A Seder
Journal:  Nat Med       Date:  2018-03-19       Impact factor: 53.440

View more
  9 in total

1.  Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya.

Authors:  Kevin O Ochwedo; Fredrick O Ariri; Wilfred O Otambo; Edwin O Magomere; Isaiah Debrah; Shirley A Onyango; Pauline W Orondo; Harrysone E Atieli; Sidney O Ogolla; Antony C A Otieno; Wolfgang R Mukabana; Andrew K Githeko; Ming-Chieh Lee; Guiyun Yan; Daibin Zhong; James W Kazura
Journal:  Front Genet       Date:  2022-05-17       Impact factor: 4.772

2.  Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230.

Authors:  Kazutoyo Miura; Eizo Takashima; Thao P Pham; Bingbing Deng; Luwen Zhou; Wei-Chiao Huang; Ababacar Diouf; Yonas T Gebremicale; Mayumi Tachibana; Tomoko Ishino; C Richter King; Jonathan F Lovell; Carole A Long; Takafumi Tsuboi
Journal:  NPJ Vaccines       Date:  2022-01-13       Impact factor: 7.344

3.  Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate.

Authors:  Pornpawee Sookpongthai; Korawich Utayopas; Thassanai Sitthiyotha; Theerakamol Pengsakul; Morakot Kaewthamasorn; Kittikhun Wangkanont; Pongchai Harnyuttanakorn; Surasak Chunsrivirot; Sittiporn Pattaradilokrat
Journal:  Parasit Vectors       Date:  2021-11-08       Impact factor: 3.876

4.  The transcriptome from asexual to sexual in vitro development of Cystoisospora suis (Apicomplexa: Coccidia).

Authors:  Teresa Cruz-Bustos; Anna Sophia Feix; Manolis Lyrakis; Marlies Dolezal; Bärbel Ruttkowski; Anja Joachim
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

Review 5.  Plasmodium 6-Cysteine Proteins: Functional Diversity, Transmission-Blocking Antibodies and Structural Scaffolds.

Authors:  Frankie M T Lyons; Mikha Gabriela; Wai-Hong Tham; Melanie H Dietrich
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

6.  Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.

Authors:  Brandon McLeod; Moustafa T Mabrouk; Kazutoyo Miura; Rashmi Ravichandran; Sally Kephart; Sophia Hailemariam; Thao P Pham; Anthony Semesi; Iga Kucharska; Prasun Kundu; Wei-Chiao Huang; Max Johnson; Alyssa Blackstone; Deleah Pettie; Michael Murphy; John C Kraft; Elizabeth M Leaf; Yang Jiao; Marga van de Vegte-Bolmer; Geert-Jan van Gemert; Jordache Ramjith; C Richter King; Randall S MacGill; Yimin Wu; Kelly K Lee; Matthijs M Jore; Neil P King; Jonathan F Lovell; Jean-Philippe Julien
Journal:  Immunity       Date:  2022-08-16       Impact factor: 43.474

7.  Quantifying Reductions in Plasmodium falciparum Infectivity to Mosquitos: A Sample Size Calculator to Inform Clinical Trials on Transmission-Reducing Interventions.

Authors:  Jordache Ramjith; Manon Alkema; John Bradley; Alassane Dicko; Chris Drakeley; Will Stone; Teun Bousema
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

8.  The methods and advances of adaptive immune receptors repertoire sequencing.

Authors:  Hongmei Liu; Wenjing Pan; Congli Tang; Yujie Tang; Haijing Wu; Akihiko Yoshimura; Yan Deng; Nongyue He; Song Li
Journal:  Theranostics       Date:  2021-08-19       Impact factor: 11.556

9.  Persistent Plasmodium falciparum infections enhance transmission-reducing immunity development.

Authors:  Ruth Ayanful-Torgby; Esther Sarpong; Hamza B Abagna; Dickson Donu; Evans Obboh; Benedicta A Mensah; Joshua Adjah; Kim C Williamson; Linda E Amoah
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.